Blending Treatments Worldwide for Multiple Myeloma

David S. Siegel, MD, PhD

Video Categories: Hematological Malignancies

David S. Siegel, MD, PhD, at the John Theurer Cancer Center in Hackensack, NJ, explains the benefits of worldwide clinical trials in creating more consistent, less toxic treatment options for multiple myeloma. New drugs are coming along, and the clinical trials for those drugs are beginning to mature.
June 16, 2015

The Biomarker: Melanoma

PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.

January 30, 2014

Benefits of Congresses and Journals in Educating on Personalized Medicine

Dr Agarwala provides his perspective on the importance of the Global Biomarkers Consortium, World Cutaneous Malignancies Congress and the journal Personalized Medicine in Oncology.